Search





Search





Enliven Therapeutics Inc

ELVN

Add to Watchlist

58.810USD

+0.750+1.29%

Close 08-14 16:00（ET）Quotes delayed by 15 min

4.31BMarket Cap

LossP/E TTM

Enliven Therapeutics Inc

58.810

+0.750+1.29%

Financial Summary Income Statement Balance Sheet Cash Flow Statement Earnings Company Valuation Risk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial Summary Income Statement Balance Sheet Cash Flow Statement Earnings Company Valuation Risk Assessment

ELVN Cash Flow Statement

You can access the annual and quarterly cash flow statements of Enliven Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q2

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

FY2020Q2

FY2020Q1

FY2019Q2

FY2019Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-8.64%-18.53M

20.04%-19.29M

7.93%-15.84M

-8.91%-13.28M

16.53%-17.06M

-3.28%-24.13M

-37.82%-17.20M

23.29%-12.19M

-69.60%-20.43M

-12.08%-23.36M

-563.94%-12.48M

-278.34%-15.89M

2.26%-12.05M

-21.47%-20.84M

84.94%-1.88M

61.46%-4.20M

-18.93%-12.33M

-31.80%-17.16M

-50.99%-12.48M

-5.36%-10.90M

-11.98%-10.37M

-36.66%-13.02M

---8.27M

---10.35M

-79.80%-9.26M

-295.80%-9.53M

---5.15M

---2.41M

Net income from continuing operations

-28.22%-32.48M

17.23%-23.63M

-27.99%-29.67M

12.99%-20.15M

-26.99%-25.34M

-25.53%-28.54M

-19.67%-23.18M

-11.49%-23.16M

-19.31%-19.95M

-54.43%-22.74M

-160.18%-19.37M

-350.62%-20.77M

-46.05%-16.72M

-0.58%-14.72M

324.77%32.19M

66.23%-4.61M

13.01%-11.45M

-42.72%-14.64M

-24.32%-14.32M

-9.85%-13.65M

-28.98%-13.16M

-42.16%-10.26M

---11.52M

---12.42M

-89.07%-10.20M

-72.03%-7.21M

---5.40M

---4.19M

Operating gains losses

-91.36%7.00K

-81.08%14.00K

-42.50%46.00K

-22.50%62.00K

3.85%81.00K

-6.33%74.00K

2.56%80.00K

5.41%78.00K

17.91%79.00K

--78.00K

-25.00%78.00K

-84.68%74.00K

168.00%67.00K

----

333.33%104.00K

1832.00%483.00K

0.00%25.00K

8.70%25.00K

-4.00%24.00K

0.00%25.00K

4.17%25.00K

--23.00K

--25.00K

--24.00K

----

--0.00

Other non-cash items

298.13%637.00K

797.50%359.00K

-86.09%147.00K

-127.90%-221.00K

130.59%160.00K

106.87%40.00K

161.81%1.06M

145.10%792.00K

37.06%-523.00K

---582.00K

-170900.00%-1.71M

-8880.00%-1.76M

-2870.00%-831.00K

----

-101.92%-1.00K

17.65%20.00K

-3.23%30.00K

-12.73%48.00K

-70.95%52.00K

134.69%17.00K

338.46%31.00K

1000.00%55.00K

--179.00K

---49.00K

---13.00K

--5.00K

----

--0.00

Change in working capital

-293.29%-605.00K

-37.58%-3.43M

339.02%1.22M

-103.15%-157.00K

107.14%313.00K

46.15%-2.50M

-109.33%-510.00K

58.25%4.99M

-455.27%-4.38M

45.14%-4.63M

1837.59%5.46M

1559.26%3.15M

169.48%1.23M

-131.48%-8.45M

-63.80%282.00K

-112.69%-216.00K

-197.42%-1.78M

3.69%-3.65M

-67.10%779.00K

16.66%1.70M

372.28%1.82M

-40.32%-3.79M

--2.37M

--1.46M

642.31%386.00K

-259.63%-2.70M

--52.00K

--1.69M

-Change in prepaid expenses

-442.71%-2.16M

1183.55%1.65M

-229.48%-694.00K

-82.25%139.00K

83.72%-398.00K

95.83%-152.00K

-90.12%536.00K

132.34%783.00K

-850.00%-2.44M

40.18%-3.64M

298.31%5.42M

-69.80%337.00K

-80.96%326.00K

-89.66%-6.09M

84.05%1.36M

-22.01%1.12M

851.11%1.71M

-24.13%-3.21M

-48.61%740.00K

105.60%1.43M

148.78%180.00K

-15.86%-2.59M

--1.44M

--696.00K

-34.18%-369.00K

-1486.34%-2.23M

---275.00K

--161.00K

-Change in other current assets

----

---2.50M

----

32.61%-310.00K

100.31%2.00K

99.97%-1.00K

0.00%-1.00K

-380.49%-460.00K

-251.40%-651.00K

-243.26%-2.90M

99.96%-1.00K

-80.71%164.00K

0.23%430.00K

92.49%2.02M

-246.19%-2.23M

--850.00K

--429.00K

127.71%1.05M

-207.17%-643.00K

--462.00K

--600.00K

-Change in other current liabilities

----

---7.00K

---6.00K

-118.75%-6.00K

---5.00K

--32.00K

--0.00

Cash from non-recurring investing activities

Cash from operating activities

-8.64%-18.53M

20.04%-19.29M

7.93%-15.84M

-8.91%-13.28M

16.53%-17.06M

-3.28%-24.13M

-37.82%-17.20M

23.29%-12.19M

-69.60%-20.43M

-12.08%-23.36M

-563.94%-12.48M

-278.34%-15.89M

2.26%-12.05M

-21.47%-20.84M

84.94%-1.88M

61.46%-4.20M

-18.93%-12.33M

-31.80%-17.16M

-50.99%-12.48M

-5.36%-10.90M

-11.98%-10.37M

-36.66%-13.02M

---8.27M

---10.35M

-79.80%-9.26M

-295.80%-9.53M

---5.15M

---2.41M

Investing cash flow

Net cash from continuing investing activities

-28.78%99.00K

-100.00%0.00

---213.00K

-104.55%-1.00K

6850.00%139.00K

0.00%20.00K

-100.00%0.00

37.50%22.00K

-97.73%2.00K

-35.48%20.00K

100.04%14.00K

-23.81%16.00K

-57.49%88.00K

-77.04%31.00K

---35.00M

--21.00K

--207.00K

1025.00%135.00K

100.00%0.00

--0.00

-100.00%0.00

-20.00%12.00K

---4.00K

--0.00

-91.36%7.00K

--15.00K

--81.00K

--0.00

Capital expenditures

-28.78%99.00K

-100.00%0.00

--0.00

----

6850.00%139.00K

0.00%20.00K

-100.00%0.00

37.50%22.00K

-97.73%2.00K

-35.48%20.00K

--14.00K

-23.81%16.00K

-57.49%88.00K

-77.04%31.00K

--0.00

--21.00K

--207.00K

1025.00%135.00K

--0.00

-100.00%0.00

-20.00%12.00K

----

--0.00

-91.36%7.00K

--15.00K

--81.00K

--0.00

Net cash flow from disposal of fixed assets

-28.78%99.00K

-100.00%0.00

---213.00K

-104.55%-1.00K

6850.00%139.00K

0.00%20.00K

-100.00%0.00

37.50%22.00K

-97.73%2.00K

-35.48%20.00K

100.04%14.00K

-23.81%16.00K

-57.49%88.00K

-77.04%31.00K

---35.00M

--21.00K

--207.00K

1025.00%135.00K

100.00%0.00

--0.00

-100.00%0.00

-20.00%12.00K

---4.00K

--0.00

-91.36%7.00K

--15.00K

--81.00K

--0.00

Net cash flow from investment products

-140.65%-441.47M

2838.91%42.53M

1573.45%12.17M

-127.34%-4.06M

-444.96%-183.45M

108.10%1.45M

-98.12%727.00K

141.79%14.85M

77.77%-33.66M

---17.86M

467.45%38.70M

-253.79%-35.53M

-2435.80%-151.43M

----

147.06%6.82M

361.61%23.11M

91.35%6.48M

-70.13%5.47M

-168.33%-14.49M

14.10%-8.83M

110.46%3.39M

283.80%18.32M

--21.21M

---10.28M

---32.40M

--4.77M

----

--0.00

Net cash flow from other investing activities

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

-140.52%-441.57M

2880.10%42.53M

1602.75%12.38M

-127.37%-4.06M

-445.34%-183.59M

107.98%1.43M

-98.12%727.00K

141.71%14.83M

77.78%-33.66M

-57593.55%-17.89M

-7.49%38.69M

-254.00%-35.55M

-2514.24%-151.52M

-100.58%-31.00K

388.59%41.82M

361.37%23.08M

85.24%6.28M

-70.85%5.33M

-168.32%-14.49M

14.10%-8.83M

110.45%3.39M

284.76%18.30M

--21.21M

---10.28M

-39909.88%-32.41M

--4.76M

---81.00K

--0.00

Financing cash flow

Cash flow from continuous financing activities

112.21%463.42M

4196.15%10.05M

-98.44%623.00K

-132.95%-368.00K

11991.81%218.38M

-99.74%234.00K

44313.33%39.97M

362.82%1.12M

164.04%1.81M

-61.98%90.27M

107.30%90.00K

---425.00K

---2.82M

--237.44M

-12230.00%-1.23M

-100.00%0.00

-101.68%-10.00K

34708.15%46.99M

-82.70%1.66M

-99.47%460.00K

--597.00K

--135.00K

482.10%9.59M

97.05%86.56M

--1.65M

--43.93M

Net cash flow from common stock issuance/repurchase

99.87%433.83M

----

-99.51%193.00K

---458.00K

1446926.67%217.05M

-100.00%0.00

--39.52M

--0.00

--15.00K

--90.00M

----

-100.00%0.00

----

--1.00K

--47.12M

-84.57%1.70M

----

--0.00

--11.02M

--69.41M

----

--0.00

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

-60.96%17.15M

--1.65M

--43.93M

Proceeds from stock option exercised by employees

2134.67%29.59M

4196.15%10.05M

16.56%528.00K

-81.29%209.00K

-26.07%1.32M

-13.33%234.00K

403.33%453.00K

3889.29%1.12M

1170.21%1.79M

92.86%270.00K

--90.00K

--28.00K

--141.00K

--140.00K

--0.00

-100.00%0.00

-29.95%145.00K

11.47%243.00K

--472.00K

--597.00K

--207.00K

--218.00K

----

Net cash flow from other financing activities

--433.83M

--0.00

---98.00K

---119.00K

----

--0.00

100.00%0.00

-100.00%0.00

100.00%0.00

---453.00K

---2.96M

--237.30M

-11109.09%-1.23M

100.00%0.00

---11.00K

-276.39%-271.00K

82.75%-284.00K

---12.00K

--0.00

---72.00K

---1.65M

----

Net cash from non-recurrent financing activities

Net cash from financing activities

112.21%463.42M

4196.15%10.05M

-98.44%623.00K

-132.95%-368.00K

11991.81%218.38M

-99.74%234.00K

44313.33%39.97M

362.82%1.12M

164.04%1.81M

-61.98%90.27M

107.30%90.00K

---425.00K

---2.82M

--237.44M

-12230.00%-1.23M

-100.00%0.00

-101.68%-10.00K

34708.15%46.99M

-82.70%1.66M

-99.47%460.00K

--597.00K

--135.00K

482.10%9.59M

97.05%86.56M

--1.65M

--43.93M

Net cash flow

Beginning cash balance

29.97%132.18M

-20.35%98.90M

1.05%101.73M

23.23%119.44M

-31.84%101.70M

23.93%124.17M

36.23%100.67M

-22.93%96.92M

-48.92%149.22M

32.55%100.19M

49.32%73.90M

310.90%125.77M

696.96%292.16M

55.91%75.59M

-34.42%49.49M

-36.51%30.61M

-31.52%36.66M

1.46%48.48M

120.38%75.47M

-11.92%48.21M

-38.34%53.53M

851.15%47.79M

--34.25M

--54.74M

77.52%86.81M

-31.94%5.02M

--48.90M

--7.38M

Current period cash flow changes

-81.27%3.32M

248.17%33.29M

-112.07%-2.84M

-572.13%-17.70M

133.91%17.73M

-145.83%-22.47M

-10.64%23.50M

107.23%3.75M

68.57%-52.29M

-77.36%49.02M

-32.07%26.29M

-374.68%-51.87M

-2649.74%-166.39M

1931.42%216.57M

243.43%38.71M

-30.72%18.88M

-13.80%-6.05M

-305.90%-11.82M

-299.31%-26.99M

233.01%27.26M

83.42%-5.32M

-92.98%5.74M

--13.54M

---20.49M

-795.59%-32.07M

96.98%81.79M

---3.58M

--41.52M

Ending cash balance

13.45%135.50M

29.97%132.18M

-20.35%98.90M

1.05%101.73M

23.23%119.44M

-31.84%101.70M

23.93%124.17M

36.23%100.67M

-22.93%96.92M

-48.92%149.22M

13.60%100.19M

49.32%73.90M

310.90%125.77M

696.96%292.16M

81.91%88.20M

-34.42%49.49M

-36.51%30.61M

-31.52%36.66M

1.46%48.48M

120.38%75.47M

-11.92%48.21M

-38.34%53.53M

--47.79M

--34.25M

20.78%54.74M

77.52%86.81M

--45.32M

--48.90M

Free cash flow

-8.34%-18.63M

20.11%-19.29M

7.93%-15.84M

-8.71%-13.28M

15.86%-17.20M

-3.28%-24.15M

-37.67%-17.20M

23.22%-12.21M

-68.39%-20.44M

-12.00%-23.38M

-564.68%-12.50M

-276.84%-15.91M

3.17%-12.14M

-20.70%-20.88M

84.94%-1.88M

61.27%-4.22M

-20.93%-12.53M

-32.71%-17.30M

-50.99%-12.48M

-5.36%-10.90M

-11.90%-10.37M

-36.58%-13.03M

---8.27M

---10.35M

-77.15%-9.26M

-296.43%-9.54M

---5.23M

---2.41M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Enliven Therapeutics Inc Generate?



Enliven Therapeutics Inc generated -70.30M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Enliven Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Enliven Therapeutics Inc's operating cash flow increased by 3.95% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Enliven Therapeutics Inc Spend on Capital Expenditures?



Enliven Therapeutics Inc spent 158.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Enliven Therapeutics Inc's Financing Cash Flow Changed?



Enliven Therapeutics Inc used 218.87M in financing activities in the latest quarter.

What is free cash flow and why does it matter for ELVN?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Enliven Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -70.46M reflecting a 3.79% change from the previous year.